drugset / Trial / NCT04147650

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

NCT04147650

Phase 2/3 Completed 508 enrolled Aurinia Pharmaceuticals Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Multi-Center, Phase 2/3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Voclosporin Ophthalmic Solution (0.05%, 0.10%, 0.20%) Compared to Vehicle in Subjects with Dry Eye Syndrome.

Timeline

Start
2019-10-14
Primary completion
2020-09-17
Completion
2020-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Voclosporin Other / unclassified 0.05 % Topical
Subject Voclosporin Other / unclassified 0.1 % Topical
Subject Voclosporin Other / unclassified 0.2 % Topical

Indications